S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

ResMed (RMD) Earnings Date, Estimates & Call Transcripts

$159.64
+1.91 (+1.21%)
(As of 12/1/2023 ET)
Compare
Today's Range
$156.39
▼
$159.74
50-Day Range
$134.74
▼
$159.63
52-Week Range
$132.24
▼
$243.52
Volume
704,931 shs
Average Volume
1.07 million shs
Market Capitalization
$23.48 billion
P/E Ratio
25.92
Dividend Yield
1.20%
Price Target
$202.33
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Jan. 25Estimated
Actual EPS
(Oct. 26)
$1.64 Beat By $0.01
Consensus EPS
(Oct. 26)
$1.63
Read Call Transcript
Listen to Call
Latest SEC 10-Q Filing
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

RMD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RMD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ResMed Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20233$1.46$1.55$1.50
Q2 20233$1.59$1.63$1.60
Q3 20234$1.56$1.59$1.58
Q4 20234$1.62$1.78$1.68
FY 202314$6.23$6.55$6.36
Q1 20243$1.59$1.66$1.63
Q2 20243$1.74$1.79$1.77
Q3 20243$1.80$1.82$1.81
Q4 20243$1.84$1.93$1.88
FY 202412$6.97$7.20$7.09
Q1 20252$1.90$1.91$1.91
Q2 20252$1.99$2.00$2.00
Q3 20251$1.95$1.95$1.95
Q4 20251$1.89$1.89$1.89
FY 20256$7.73$7.75$7.74
Q1 20261$2.09$2.09$2.09

RMD Earnings Date and Information

ResMed last released its quarterly earnings results on October 26th, 2023. The medical equipment provider reported $1.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.63 by $0.01. The company earned $1.10 billion during the quarter, compared to analysts' expectations of $1.10 billion. Its revenue for the quarter was up 16.0% on a year-over-year basis. ResMed has generated $6.16 earnings per share over the last year ($6.16 diluted earnings per share) and currently has a price-to-earnings ratio of 25.9. Earnings for ResMed are expected to grow by 9.88% in the coming year, from $7.29 to $8.01 per share. ResMed has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, January 25th, 2024 based off prior year's report dates.

ResMed Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
1/25/2024
Estimated)		------- 
10/26/2023Q1 2024$1.63$1.64+$0.01$1.79$1.10 billion$1.10 billion      
8/3/2023Q4 2023$1.67$1.60($0.07)$1.64$1.14 billion$1.12 billion    
4/27/2023Q3 2023$1.58$1.68+$0.10$1.78$1.05 billion$1.12 billion    
1/26/2023Q2 2023$1.62$1.66+$0.04$1.79$996.22 million$1.03 billion    
10/27/2022Q1 2023$1.51$1.51-$1.59$946.07 million$950.30 million    
8/11/2022Q4 2022$1.48$1.49+$0.01$1.65$912.53 million$914.74 million      
4/28/2022Q3 2022$1.44$1.32($0.12)$1.42$900.03 million$864.50 million    
1/27/2022Q2 2022$1.47$1.47-$1.57$927.49 million$894.60 million    
10/28/2021Q3 2021$1.35$1.51+$0.16$1.63$858.20 million$904.00 million    
8/5/2021Q2 2021$1.25$1.35+$0.10$1.37$781.10 million$876.10 million    
4/29/2021Q3$1.22$1.30+$0.08$3.14$784.47 million$768.77 million  
1/28/2021Q4 2020$1.22$1.41+$0.19$1.59$785.07 million$800.00 million  












ResMed Earnings - Frequently Asked Questions

When is ResMed's earnings date?

ResMed has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, January 25th, 2024 based off last year's report dates. Learn more on RMD's earnings history.

Did ResMed beat their earnings estimates last quarter?

In the previous quarter, ResMed (NYSE:RMD) reported $1.64 earnings per share (EPS) to beat the analysts' consensus estimate of $1.63 by $0.01. Learn more on analysts' earnings estimate vs. RMD's actual earnings.

How can I listen to ResMed's earnings conference call?

The conference call for ResMed's latest earnings report can be listened to online. Listen to Conference Call

How can I read ResMed's conference call transcript?

The conference call transcript for ResMed's latest earnings report can be read online. Read Transcript

How can I view ResMed's earnings report?

ResMed's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does ResMed generate each year?

ResMed (NYSE:RMD) has a recorded annual revenue of $4.22 billion.

How much profit does ResMed generate each year?

ResMed (NYSE:RMD) has a recorded net income of $897.56 million. RMD has generated $6.16 earnings per share over the last four quarters.

What is ResMed's price-to-earnings ratio?

ResMed (NYSE:RMD) has a trailing price-to-earnings ratio of 25.92 and a forward price-to-earnings ratio of 21.90. The price/earnings-to-growth ratio is 2.7.

What is ResMed's EPS forecast for next year?

ResMed's earnings are expected to grow from $7.29 per share to $8.01 per share in the next year, which is a 9.88% increase.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NYSE:RMD) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -